#ESMO17: Bristol-Myers posts data on an upset checkpoint combo victory in frontline kidney cancer
Madrid — There may be five PD-(L)1 drugs on the market, but they’re still continuing to produce surprising results in clinical trials.
The latest upset …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
